Economic impact of lawsuits for drug supply in the State of São Paulo
Objective: to understand the participation of expenses with judicialized medicines in total expenditure on drugs (DTLM) in São Paulo State (SP). Methods: it was conducted an exploratory analysis of data from Sistema de Informações Gerenciais da Execução Orçamentária (Sigeo) and Sistema de Informação...
| Autores: | , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | Brasil |
| Recursos: | Fundação Oswaldo Cruz (FIOCRUZ) |
| Repositorio: | Cadernos Ibero-Americanos de Direito Sanitário (Online) |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs.cadernos.prodisa.fiocruz.br:article/565 |
| Acesso em linha: | https://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/565 |
| Access Level: | acceso abierto |
| Palavra-chave: | Custos de medicamentos. Custos e análise de custo. Judicialização da saúde. Assistência farmacêutica. Drug costs. Costs and cost analysis. Health judicialization. Pharmaceutical services. Costos de los medicamentos. Costos y análisis de costo. Judicialización de la salud. Servicios farmacéuticos. |
| Resumo: | Objective: to understand the participation of expenses with judicialized medicines in total expenditure on drugs (DTLM) in São Paulo State (SP). Methods: it was conducted an exploratory analysis of data from Sistema de Informações Gerenciais da Execução Orçamentária (Sigeo) and Sistema de Informação de Orçamento Público em Saúde (Siops) from 2010 to 2018. Results: in this period, DTLM in SP exceeded 11 billion of reais, showing a downward trend in global values and percentage share in relation to total health expenditure (from 11.32% in 2010 to 8.95% in 2018). From 2016 to 2018, 17% of DTLM were destined to lawsuits (R$ 679,935,967.31), with a growing trend. Discussion: the representativeness of judicialized drugs in DTLM warns of cost issues, but also for patient safety and sustainability of public health policies, because this list also includes new drugs, which have not been proved superior in effectiveness and safety yet, comparing to available alternatives, and/or off label use. Conclusions: the legal demands for medicines have not led to an increase in the allocation of funds for their purchase, but to competition for resources originally destinated for the pharmaceutical services policy, with a reduction in the percentage participation of medicines from SUS official lists each year. |
|---|